High-density lipoprotein mimetics: promises and challenges

Apolipoprotein A-I mimetics and high-density lipoprotein function.

PURPOSE OF REVIEW To review recently published advances in the development of apolipoprotein A-I (apoA-I) mimetic peptides as a potential treatment for cardiovascular diseases. RECENT FINDINGS Various apoA-I mimetic peptides are currently in development and these display potent cardioprotective features that can rival or even surpass those of full length apoA-I and high-density lipoproteins (...

High-density lipoprotein and cardiovascular risk reduction: promises and realities.

In a recent article in the Revista Española de Cardiologı́a, Cordero et al. reported a study of the concentrations of high-density lipoprotein cholesterol (HDL-C) in 959 unselected consecutive patients who were admitted for chest pain. The authors found that low levels of HDL-C (<40 mg/dL) were independently associated with diagnosis of acute coronary syndrome (ACS), that is, the lower the level...

Advances in high-density lipoprotein physiology: surprises, overturns, and promises.

Emerging evidence strongly supports that changes in the HDL metabolic pathway, which result in changes in HDL proteome and function, appear to have a causative impact on a number of metabolic disorders. Here, we provide a critical review of the most recent and novel findings correlating HDL properties and functionality with various pathophysiological processes and disease states, such as obesit...

High density Lipoprotein; What to Measure: Quality or Quantity?

High -density lipoprotein cholesterol as a predictor for diabetes mellitus

Background: Diabetes is a prevalent chronic disease around the world. To evaluate risk of diabetes comprehensively, we developed a score model for the risk prediction with HDL-C as a protective factor. Methods: We extracted physical examination data of 2728 individuals. The data contain 18 demographic and clinical variables. To identify the statistical significant feature variables, the backwa...